New insights on diagnosis and treatment of AVP deficiency

Julie Refardt*, Cihan Atila, Mirjam Christ-Crain

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

4 Citations (Scopus)
1 Downloads (Pure)


Arginine vasopressin deficiency (AVP-D) is one of the main entities of the polyuria-polydipsia syndrome. Its correct diagnosis and differentiation from the other two causes - AVP resistance and primary polydipsia – is crucial as this determines the further management of these patients. Over the last years, several new diagnostic tests using copeptin, the stable surrogate marker of AVP, have been introduced. Among them, hypertonic saline stimulated copeptin was confirmed to reliably and safely improve the diagnostic accuracy to diagnose AVP-D. Due to its simplicity, arginine stimulated copeptin was put forward as alternative test procedure. Glucagon-stimulated copeptin also showed promising results, while the oral growth hormone secretagogue Macimorelin failed to provide a sufficient stimulus. Interestingly, an approach using machine learning techniques also showed promising results concerning diagnostic accuracy. Once AVP-D is diagnosed, further workup is needed to evaluate its etiology. This will partly define the further treatment and management. In general, treatment of AVP-D focuses on desmopressin substitution, with oral formulations currently showing the best tolerance and safety profile. However, in addition to desmopressin substitution, recent data also showed that psychopathological factors play an important role in managing AVP-D patients.

Original languageEnglish
Pages (from-to)639-649
Number of pages11
JournalReviews in Endocrine and Metabolic Disorders
Issue number3
Publication statusPublished - Jun 2024

Bibliographical note

Publisher Copyright:
© The Author(s) 2023.


Dive into the research topics of 'New insights on diagnosis and treatment of AVP deficiency'. Together they form a unique fingerprint.

Cite this